老年医学研究

参考文献

[1] BAGGIO LL,DRUCKER DJ. Biology of incretins:GLP-1 and GIP[J]. Gastroenterology,2007,132(6):2131-2157.

[2]赵洁，王丽宏，车慧.胰高血糖素样肽-1受体激动剂的研究进展[J].中国医师进修杂志，2019,42(11):1053-1056.

[3] JONESA B,BLOOMA SR,BUENAVENTURAB T,et al. Control of insulin secretion by GLP-1[J]. Peptides,2018,100:75-84.

[4] ALARCON C,WICKSTEED B,RHODES CJ. Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level[J]. Diabetologia,2006,49(12):2920-2929.

[5] BLONDE L,JENDLE J,GROSS J,et al. Once-weekly dulaglutide versus bedtime insulin glargine,both in combination with prandial insulin lispro, in patients with type 2 diabetes(AWARD-4):a randomised,open-label,phase 3,non-inferiority study[J]. Lancet,2015,385:2057-2066.

[6] LEVIN PA,NGUYEN H,WITTBRODT ET,et al. Glucagonlike peptide-1 receptor agonists:a systematic review of comparative effectiveness research[J]. Diabetes Metab Syndr Obes,2017,10:123-139.

[7]徐斯盛，华小懿，肖兰，等.新型长效胰高血糖素样肽-1受体激动药——杜拉鲁肽[J].中国药房，2015,26(32):4593-4595.

[8] SEGHIERI M,REBELOS E,GASTALDELLI A,et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans[J]. Diabetologia,2013,56(1):156-161.

[9] ZANDER M,MADSBAD S,MADSEN JL,et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control,insulin sensitivity,andβ-cell function in type 2 diabetes:a parallelgroup study[J]. Lancet,2002,359(9309):824-830.

[10] TONG J,D'ALESSIO D. Give the receptor a brake:slowing gastric emptying by GLP-1[J]. Diabetes,2014,63(2):407-409.

[11] KANOSKI SE,HAYES MR,SKIBICKA KPAND. GLP-1 and weight loss:unraveling the diverse neural circuitry[J]. Am J Physiol Regul Integr Comp Physiol,2016,310(10):R885-R895.

[12] BEIROA D,IMBERNON M,GALLEGO R,et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK[J]. Diabetes,2014,63(10):3346-3358.

[13] GIRI B,DEY S,DAS T,et al. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction,infection,cancer progression and other pathophysiological consequences:an update on glucose toxicity[J]. Biomed Pharmacother,2018,107:306-328.

[14] ROSSETTI L,GIACCARI A,DEFRONZO RA. Glucose toxidty[J]. Diabetes Care,1990,13(6):610-630.

[15] LIST JF,HABENER JF. Glucagon-like peptide 1 agonists and the development and growth of pancreaticβ-cells[J]. Am J Physiol Endocrinol Metab,2004,286(6):E875-E881.

[16] DUNGAN KM,POVEDANO ST,FORST T,et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes(AWARD-6):a randomised,open-label,phase 3,non-inferiority trial[J]. Lancet,2014,384(9951):1349-1357.

[17] ODAWARA M,MIYAGAWA J,IWAMOTO N,et al. Onceweekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes:52 weeks of treatment in a randomized phaseⅢstudy[J]. Diabetes Obes Metab,2016,18(3):249-257.

[18] MORIERI ML,RIGATO M,FRISON V,et al. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A realworld study and meta-analysis of observational studies[J]. Metabolism,2020,106:154190.

[19] WYSHAM C,BLEVINS T,ARAKAKI R,et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial(AWARD-1)[J]. Diabetes Care,2014,37(8):2159-2167.

[20] GENTILELLA R,ROMERA I,NICOLAY C,et al. Change in HbA1cacross the baseline HbA1crange in type 2 diabetes patients receiving once-weekly dulaglutide versus other incretin agents[J]. Diabetes Ther,2019,10(3):1113-1125.

[21] SHI LX,LIU XM,SHI YQ,et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes:post-hoc analyses of a randomized,doubleblind,phaseⅢstudy[J]. J Diabetes Investig,2020,11(1):142-150.

[22] SHI FH,LI H,CUI M,et al. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes:a systematic review and meta-analysis of randomized controlled trials[J]. Frontiers in Pharmacology,2018,9:576.

[23] NAUCK MA,PETRIE JR,SESTI G,et al. A Phase 2,randomized,dose-finding study of the novel once-weekly human GLP-1analog,semaglutide,compared with placebo and open-label liraglutide in patients with type 2 diabetes[J]. Diabetes Care,2016,39(2):231-241.

[24]姜露，厉平. GLP-1类似物和受体激动剂对2型糖尿病合并肥胖及单纯肥胖患者体重影响的研究进展[J].医学综述，2020,26(2):341-345.

[25] ZHANG F,TONG YZ,SU N,et al. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes:a systematic review and meta-analysis of randomized controlled trials[J]. J Diabetes,2015,7(3):329-339.

[26] VILSBOLL T,CHRISTENSEN M,JUNKER AE,et al. Effects of glucagonlike peptide-1 receptor agonists on weight loss:systematic review and meta-analyses of randomised controlled trials[J]. BMJ,2012,344:d7771.

[27] FERDINAND KC,WHITE WB,CALHOUN DA,et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus[J]. Hypertension,2014,64(4):731-737.

[28] MARSO SP,BAIN SC,CONSOLI A,et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med,2016,375(19):1834-1844.

[29]葛均波，霍勇，高秀芳，等.改善心血管和肾脏结局的新型抗高血糖药物临床应用中国专家建议[J].中华高血压杂志，2020,28(3):31-39.

[30] ZELNIKER TA,WIVIOTT SD,RAZ I,et al. Comparison of the effects of glucagon-lLike peptide receptor agonists and sodiumglucose co-transporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus:a systematic review and meta-analysis of cardiovascular outcomes trials[J]. Circulation,2019,139(17):2022-2031.

[31] GERSTEIN HC,COLHOUN HM,DAGENAIS GR,et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes(REWIND):a double-blind,randomised placebo-controlled trial[J]. Lancet,2019,394(10193):121-130.

[32] MARSO SP,DANIELS GH,FRANDSEN KB,et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2016,375(4):311-322.

[33]纪立农，邹大进，洪天配，等. GLP-1受体激动剂临床应用专家指导意见[J].中国糖尿病杂志，2018,26(5):353-361.

[34] HUANG D,REFAAT M,MOHAMMEDI K,et al. Macrovascular vomplications in patients with diabetes and prediabetes[J].Biomed Res Int,2017,2017:7839101.

[35] AMERICAN DIABETES ASSOCIATION. Cardiovascular disease and risk management:standards of medical care in diabetesd2020[J]. Diabetes Care,2020,43(Suppl 1):S111-S134.

[36] ANDRIKOU E,TSIOUFIS C,ANDRIKOU I,et al. GLP-1 receptor agonists and cardiovascular outcome trials:an update[J].Hellenic J Cardiol,2019,60(6):347-351.

[37] TUTTLE KR,LAKSHMANAN MC,RAYNER B,et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease(AWARD-7):a multicentre,open-label,randomised trial[J]. Lancet Diabetes Endocrinol,2018,6(8):605-617.

[38] MANN JFE，?RSTED DD,BROWN-FRANDSEN K,et al. Liraglutide and renal outcomes in type 2 diabetes[J]. N Engl J Med,2017,377(9):839-848.

[39] LORENZ M,LAWSON F,OWENS D,et al. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate[J]. Cardiovasc Diabetol,2017,16(1):6.

[40] JENDLE J,GRUNBERGER G,BLEVINS T,et al. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes:a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program[J]. Diabetes Metab Res Rev,2016,32(8):776-790.

[41] SKRIVANEK Z,GAYDOS BL,CHIEN JY,et al. Dose-finding results in an adaptive,seamless,randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients(AWARD-5)[J]. Diabetes Obes Metab,2014,16(8):748-756.

[42] SHAEFER CF,KUSHNER P,AGUILAR R. User,s guide to mechanism of action and clinical use of GLP-1 receptor agonists[J]. Postgrad Med,2015,127(8):818-826.

[43]房舒舒，赵华平，陈茜，等. 2型糖尿病治疗药物杜拉鲁肽的研究进展[J].临床药物治疗杂志，2018,16(2):22-26.

[44] SCOTT LJ. Dulaglutide:a review in type 2 diabetes[J]. Drugs,2020,80(2):197-208.

[45] GERSTEIN HC,COLHOUN HM,DAGENAIS GR,et al. Dulaglutide and renal outcomes in type 2 diabetes:an exploratory analysis of the REWIND randomised,placebo-controlled trial[J]. Lancet,2019,394(10193):131-138.